



Living Cell Technologies Ltd

COMPANY ANNOUNCEMENT

**Living Cell Technologies Showcases
Proprietary Nanobiocapsules at NZBio 2008**

April 2, 2008, Melbourne, Australia and Auckland, New Zealand. Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK) today announced that Dr. Paul Tan, LCT CEO and Dr. Anil K Anal, LCT Material Scientist, presented data at a session on nanotechnology at the NZBio 2008 Conference in Auckland, New Zealand. Their presentation showcased the Company's proprietary nanobiocapsules which allow encapsulated porcine insulin producing cells, DiabeCell[®], to be implanted without the use of toxic immune suppressive drugs.

On March 31, the Company reported positive early preliminary data from an on-going Phase I/IIa clinical trial which shows that following implant into patients with insulin dependent diabetes, the encapsulated porcine pancreatic islets remain functioning for at least 6 months and beneficial effects were greater than expected.

Dr. Paul Tan said, "The positive clinical effects indicate that our technology has succeeded in placing cells into gel capsules which allow oxygen and nutrients to pass inward and insulin to diffuse outward, while preventing immune agents from destroying the cells. This was achieved by layering highly selective materials to form the capsule wall with pores of the appropriate nanoscale size."

LCT has a filed patent for its nanobiocapsule technology. Dr Tan continued, "This encapsulation technology has other cell based therapeutic applications and can be used to deliver other mature cells or stem cells."

Scientific American describes nanotechnology as technology which "broadly applies to control of materials and components only a few billionths of a meter in size." LCT's nanobiocapsules are the result of controlled molecular interactions of selected polymers to produce molecular structures with pores less than 50 nanometers diameter, as seen by atomic force microscopy and confocal laser scanning microscopy.

Dr. Paul Tan CEO Mob: 0402 716 984 (AUS) 021 608 784 (NZ) Tel: +64 9 270 7941 ptan@lctglobal.com	Investor and Media Relations Rebecca Wilson Buchan Consulting P: +612 9237 2800 M: +61 (0)417 382 391 rwilson@bcg.com.au	Investor and Media Relations (U.S.) Leslie Wolf Creutzfeldt The Global Consulting Group Tel: +1-646-284-9472 lwolf-creutzfeldt@hfgcg.com
--	--	--

About Living Cell Technologies: www.lctglobal.com

Living Cell is developing cell-based products to treat life threatening human diseases. The Company owns a bio-certified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients having type 1 diabetes, the Company implants micro-encapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The company entered clinical

trials for its diabetes product in 2007. The Company is developing treatments for Huntington's disease and other neurological disorders that involve implantation of micro-encapsulated choroid plexus cells to deliver beneficial proteins and neurotrophic factors to the brain. Living Cell's technology has the potential for allowing healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. Living Cell also is developing medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes. The changes in this paragraph reflect that the company only is developing or might develop certain products, and is not manufacturing or selling any products other than DiabeCell

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information as of April 2, 2008, and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.